Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL8326 in Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT06794957Phase 1Active, not recruiting
- Sponsor
- Advenchen Laboratories
- Start
- May 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AL8326 in non-small cell lung cancer (NSCLC), sponsored by Advenchen Laboratories. Primary endpoint: Objective Remission Rate at 24 months. Started May 2022; status: active, not recruiting.
02
Drugs
AL8326
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06794957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06794957.